Calidi Biotherapeutics Inc.

Calidi Biotherapeutics announced on Friday that it received a NYSE American compliance notice for failing to meet the exchange's $4M minimum stockholders' equity requirement. The notice has no immediate impact on trading, and the stock will continue trading on NYSE American, though with a ".BC" below-compliance designation. The company must submit a compliance plan by Oct. 21, 2026, and has until March 21, 2028, to regain compliance. If the plan is rejected, not submitted, or the company fails to make sufficient progress, NYSE American could begin delisting proceedings. Despite the warning, the stock traded nearly 4% higher at ~$1.17 in the after-hours trading session.

Calidi Biotherapeutics announced a 1-for-16 reverse stock split of its outstanding common stock, effective July 31, 2026, sending shares down 15.03% in premarket trading to $0.0978. The split, approved by shareholders on June 12 and the board on July 15, will convert every 16 pre-split shares into one post-split share, with fractional shares rounded up. The company stated the move aims to optimize market dynamics, broaden investor appeal, and align trading conditions with shareholder interests. Proportionate adjustments will be made to outstanding stock options, warrants, convertible securities, and equity incentive plans, while the par value and number of authorized shares remain unchanged. The stock will trade on a split-adjusted basis on the NYSE American under the ticker CLDI, with a new CUSIP number 320703507.